Clinical Trial Results:
A phase IV study to determine the oral and genital tract concentration of Maraviroc required for ex vivo protection from HIV-1 using Maraviroc 300mg stat
Summary
|
|
EudraCT number |
2012-003778-16 |
Trial protocol |
GB |
Global end of trial date |
01 Jul 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Dec 2018
|
First version publication date |
06 Dec 2018
|
Other versions |
|
Summary report(s) |
FINAL STUDY REPORT |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
J005
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Guy's and St Thomas' NHS Foundation Trust
|
||
Sponsor organisation address |
Great Maze Pond, London, United Kingdom, SE19RT
|
||
Public contact |
Dr Julie Fox, Guy's & St. Thomas' NHS Foundation Trust, 44 02071882643, julie.fox@gstt.nhs.uk
|
||
Scientific contact |
Dr Julie Fox, Guy's & St. Thomas' NHS Foundation Trust, 44 02071882643, julie.fox@gstt.nhs.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
01 Jul 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
01 Jul 2015
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
01 Jul 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To determine concentration of Maraviroc in directly aspirated fluid and tissue from the genital tract and rectal compartments at different time periods following a single oral administration of Maraviroc 300mg in HIV-1-negative healthy volunteers
|
||
Protection of trial subjects |
Patients must refrain from drinking grapefruit juice during the study as very large quantities can affect the pharmacokinetics of Maraviroc. Patients are asked to refrain from caffeine and alcohol for 48 hours prior to dosing (if applicable) and until after biopsy.
|
||
Background therapy |
None | ||
Evidence for comparator |
N/A | ||
Actual start date of recruitment |
18 Dec 2012
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 58
|
||
Worldwide total number of subjects |
58
|
||
EEA total number of subjects |
58
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
58
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
Healthy adult volunteers were recruited through information presented in community organisations, hospitals, colleges, other institutions and/or advertisements, including email responses to expressed interest. 58 participants were recruited from two centres in London between 2013 and 2015. | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
Inclusion Criteria Male or non-pregnant, non-lactating females Age between 18 to 50 years, inclusive. Body Mass Index (BMI) of 16 to 35 kg/m2, inclusive. Negative antibody/antigen combined test for HIV-1 and HIV-2. Absence of any significant health problems (in the opinion of the investigator) | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Overall Trial (overall period)
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Blinding implementation details |
N/A
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
ARM A - CONTROL | ||||||||||||||||||
Arm description |
1st sampling at end of V2 (baseline) 2nd sampling 4 weeks post V2 No IMP administration | ||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||
Arm title
|
ARM B - MARAVIROC 300mg | ||||||||||||||||||
Arm description |
1st sampling 2 hours post 1stMaraviroc 300g stat dose 2nd sampling 24 hours post 2nd Maraviroc 300mg stat dose | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
MARAVIROC
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
CELSENTRI
|
||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
300 mg single dose administered at two timepoints one month apart.
|
||||||||||||||||||
Arm title
|
ARM C - MARAVIROC 300mg | ||||||||||||||||||
Arm description |
1st sampling 4 hours post 1stMaraviroc 300g stat dose 2nd sampling 36 hours post 2ndMaraviroc 300mg stat dose | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
MARAVIROC
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
CELSENTRI
|
||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
300 mg single dose administered at two timepoints one month apart.
|
||||||||||||||||||
Arm title
|
ARM D - MARAVIROC 300mg | ||||||||||||||||||
Arm description |
1st sampling 6 hours post 1stMaraviroc 300mg stat dose 2nd sampling 48 hours post 2ndMaraviroc 300mg stat dose | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
MARAVIROC
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
CELSENTRI
|
||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
300 mg single dose administered at two timepoints one month apart.
|
||||||||||||||||||
Arm title
|
ARM E - MARAVIROC 300mg | ||||||||||||||||||
Arm description |
1st sampling 12 hours post 1stMaraviroc 300mg stat dose 2nd sampling 72 hours post 2ndMaraviroc 300mg stat dose | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
MARAVIROC
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
CELSENTRI
|
||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
300 mg single dose administered at two timepoints one month apart.
|
||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall Trial
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
ARM A - CONTROL
|
||
Reporting group description |
1st sampling at end of V2 (baseline) 2nd sampling 4 weeks post V2 No IMP administration | ||
Reporting group title |
ARM B - MARAVIROC 300mg
|
||
Reporting group description |
1st sampling 2 hours post 1stMaraviroc 300g stat dose 2nd sampling 24 hours post 2nd Maraviroc 300mg stat dose | ||
Reporting group title |
ARM C - MARAVIROC 300mg
|
||
Reporting group description |
1st sampling 4 hours post 1stMaraviroc 300g stat dose 2nd sampling 36 hours post 2ndMaraviroc 300mg stat dose | ||
Reporting group title |
ARM D - MARAVIROC 300mg
|
||
Reporting group description |
1st sampling 6 hours post 1stMaraviroc 300mg stat dose 2nd sampling 48 hours post 2ndMaraviroc 300mg stat dose | ||
Reporting group title |
ARM E - MARAVIROC 300mg
|
||
Reporting group description |
1st sampling 12 hours post 1stMaraviroc 300mg stat dose 2nd sampling 72 hours post 2ndMaraviroc 300mg stat dose |
|
|||||||||||||||||||
End point title |
Concentration of Maraviroc in fluid and tissue [1] | ||||||||||||||||||
End point description |
Concentration of Maraviroc in fluid and tissue from the genital tract and rectal compartments at different time periods following a single oral administration of Maraviroc 300mg in HIV-1-negative healthy volunteers
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
Duration of trial maximum 6 weeks
|
||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: See attached document for results |
|||||||||||||||||||
|
|||||||||||||||||||
Attachments |
Untitled (Filename: MVC PREP RESULTS TABLES.pdf) |
||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Secondary Enpoint | ||||||||||||||||||
End point description |
Level of Maraviroc required in the plasma, vagina, rectum and urethra for 100% ex vivo protection from HIV-1(this will inform on dosing of intermittent PrEP).
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
0-6 weeks Follow up
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
0 to 6 weeks follow up visit
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
17.1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
ARM B
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
ARM C
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
ARM A
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
ARM D
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
02 Oct 2013 |
* Change in CI to Julie Fox
* Label update to reflect change in CI |
||
15 May 2014 |
Removal of Hep A from exclusion criteria |
||
29 Apr 2015 |
Additional Control group included |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |